In an attempt to isolate potential molecular targets for diagnosis, treatment and/or prevention of colorectal cancer (CRC), we have been analyzing expression profiles of clinical samples from CRC patients using genome-wide cDNA microarray. Among the genes up-regulated frequently in colorectal tumors, we here focused on TOMM34 (34 kDatranslocase of the outer mitochondrial membrane). Immunohistochemical staining revealed significant accumulation of TOMM34 protein in CRC tissues compared with their corresponding non-cancerous mucosae. Transfection of colon cancer HCT116 cells with short-interfering RNA (siRNA) specific to TOMM34 effectively suppressed its expression and drastically inhibited cell growth. These findings suggest that TOMM34 is involved in the growth of cancer cells, and may contribute to the development of novel anticancer drugs and/or diagnosis for CRC.
Introduction
Colorectal cancer is one of the most common causes of cancerdeath worldwide. Despite various advances in the diagnosis and treatment of CRC in recent decades, many patients with advanced CRC succumb to the disease. To improve prognoses, development of sensitive and specific diagnostic biomarkers for the detection of early-stage carcinomas and that of more effective and less harmful therapeutic drugs are desired. To attain this end, it is requisite to better understand the molecular mechanisms of colorectal carcinogenesis. Molecular studies have revealed that colorectal carcinogenesis involves an accumulation of genetic alternations that include genetic changes in tumor suppressor genes and/or oncogenes including APC, p53, ß-catenin and K-ras (1) (2) (3) (4) . In addition, epigenetic events such as altered methylation (5) and loss of imprinting (6) , and/or deregulated transcriptional control by genetic changes or other unknown mechanism(s) are involved in the genesis of colorectal tumors. Among the genes involved in carcinogenesis, we can expect that inhibition of gene products essential for proliferation and/or survival of cancer cells will result in their growth inhibition or cell death. Therefore, molecules that exert oncogenic activity and are specifically expressed in cancer cells represent promising targets for developing novel anti-cancer drugs.
Mitochondrial translocation machinery is a fundamental mechanism for normal mitochondrial function. It is achieved by several components including translocase of the outer membrane of mitochondria (Tom) and that of the inner membrane (Tim). Among the Tom components, Tom20 and Tom22, and Tom37 and Tom70, form heterodimeric receptor complexes that recognize target protein to translocate. Human TOMM34 was identified from human EST and cDNA databases and predicted to encode a protein containing degenerated tetratricopeptide repeat (TPR) motifs. The predicted protein shares sequence homology in a 62-residue motif with known yeast Tom70 family of mitochondrial receptors (7) . In addition, antibodies against Tom34 inhibited translocation of preprotein into mitochondria (8) . These data indicated that TOMM34 plays a role in mitochondrial import of preprotein. Investigations revealed that the NH2-terminal region of Tom34 is essential for the protein import, and that it interacts with the mature portion of some preproteins (8) . In addition, recent studies proposed a possible function of Tom to keep preproteins in unfolded importable protein conformation (9) . However, the precise role of TOMM34 remains unresolved.
To clarify the molecular mechanisms in colorectal carcinogenesis and find novel therapeutic targets for CRC, we previously performed global gene-expression profile analysis using a cDNA microarray consisting of 23040 genes (10) . In this study, we report that human TOMM34 is frequently up-regulated in CRCs, and that it is expressed abundantly in the testis and ovary, at low levels in the prostate, spleen, and colon, and barely in the other 11 normal adult tissues examined. Since suppression of TOMM34 by siRNA markedly reduced the growth of colon cancer cells, the gene product may be a potential therapeutic target for human tumors as well as a useful diagnostic maker. Semi-quantitative RT-PCR. Total RNA was extracted from cultured cells or clinical tissues using TRIzol reagent (Invitrogen) according to the manufacturer's protocol.
Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target

Materials and methods
Extracted RNA was treated with DNaseI (Roche Diagnostics, Mannheim, Germany) and reverse transcribed to singlestranded cDNAs using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and Superscript II reverse transcriptase (Invitrogen). We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR amplification by monitoring the GAPDH gene as a quantitative control. The primer sequences used were 5'-ACAACAGCCT CAAGATCATCAG-3' and 5'-GGTCCACCACTGACACGT TG-3' for GAPDH; 5'-TGGTATAAACCTAAGGCCCTG AT-3' and 5'-TAAACAGCTTAGGTGCCTCTCTG-3' for TOMM34. All of the amplification reactions were preceded by initial denaturation at 94˚C for 2 min, followed by 18 (for GAPDH) or 29 cycles (for TOMM34) of amplification at 94˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 30 sec on a GeneAmp PCR system 9700 (PE Applied Biosystems, Foster, CA).
Northern blotting. Human multiple-tissue blots (BD Bioscience, Palo Alto, CA) were hybridized with a 32 Plabeled PCR product of TOMM34. The probe was prepared by RT-PCR using a set of primers, 5'-GAACGTGAAGGCA TTCTACAGA-3' and 5'-TAAACAGCTTAGGTGCCTCTC TG-3', and subsequent random-oligonucleotide labeling with 32 P-dCTP using a Mega Label kit (Amersham Biosciences, Buckinghamshire, UK). Prehybridization, hybridization, and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at -80˚C for 10 days.
Preparation of polyclonal antibody against TOMM34. The entire coding region of TOMM34 was amplified using a set of primers, 5'-CATAAGCTTGCATGGCCCCCAAATT CCCA-3' and 5'-GTTAAGCTTTTAGTGTAGGTTCT-3', and subsequently cloned into an appropriate cloning site of pET28 vector (Novagen, Madison, WI) to generate plasmids expressing His-tagged TOMM34 protein. The recombinant protein was expressed in Escherichia coli, BL21-CodonPlus (DE3)-RIL strain (Stratagene, La Jolla, CA), and purified using TALON Superflow Metal Affinity Resin (BD Bioscience) according to the manufacturer's protocol. The protein was inoculated into rabbits, and the immunized sera were purified on affinity columns according to the standard method. Western blot analysis was carried out using proteins extracted from the cells using 0.1% RIPA like buffer containing 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 0.1% SDS, and 0.5% NP40 with Protease Inhibitor Cocktail Set III (CALBIOCHEM, La Jolla, CA).
Immunohistochemistry. Immunohistochemical staining was performed using affinity-purified polyclonal antibody against human TOMM34. The paraffin-embedded tissue sections were subjected to the SAB-PO peroxidase immunostaining system (Nichirei, Tokyo, Japan), after antigens were retrieved from deparaffinized and re-hydrated tissues by pre-treating the slides in 0.01 M citrate buffer (pH 6.0) at 108˚C for 10 min by autoclave.
Construction of psiU6BX expressing siRNAs to TOMM34. Plasmids expressing siRNAs were prepared by cloning double-stranded oligonucleotides into the BbsI site in the psiU6BX vector as described previously (11) . The sequences of paired oligonucleotides were 5'-CACCGAAAGTGTTCTC TACTCCATTCAAGAGATGGAGTAGAGAACACTTTC-3' and 5'-AAAAGAAAGTGTTCTCTACTCCATCTCTTGAA TGGAGTAGAGAACACTTTC-3' for siD; 5'-CACCGG ATGGAAACTGCAGAGACTTCAAGAGAGTCTCTGCA GTTTCCATCC-3' and 5'-AAAAGGATGGAAACTGCAGA GACTCTCTTGAAGTCTCTGCAGTTTCCATCC-3' for siE; 5'-CACCTAAAGTCTTATCTACTCCATTCAAGAGA TGGAGTAGATAAGACTTTA-3' and 5'-AAAATAAAGTC TTATCTACTCCATCTCTTGAATGGAGTAGATAAGAC TTTA-3' for siDmm; and 5'-CACCGATCTCTAGTACTAG TCCATTCAAGAGATGGACTAGTACTAGAGATC-3' and 5'-AAAAGATCTCTAGTACTAGTCCATCTCTTGAATGG ACTAGTACTAGAGATC-3' for siDscr. TOMM34-siDmm and TOMM34-siDscr expressed mutant siRNAs containing either three nucleotides substitution or scrambled sequence of TOMM34-siD, respectively. After phosphorylation with T4polynucleotide kinase, the paired oligonucleotides were boiled for 5 min, and were subsequently annealed to produce double-stranded oligonucleotides by cooling slowly. A control plasmid, psiU6BX-EGFP was prepared using 5'-CACCGAA GCAGCACGACTTCTTCTTCAAGAGAGAAGAAGTCGT GCTGCTTC-3' and 5'-AAAAGAAGCAGCACGACTTC TTCTCTCTTGAAGAAGAAGTCGTGCTGCTTC-3'. To examine the effect of TOMM34-siRNAs, Western blot analysis was carried out using anti-TOMM34 antibody five days after transfection with the plasmids.
Colony-formation assay. HCT116 cells plated on 10-cm dishes (4x10 5 cells/dish) were transiently transfected with plasmids expressing TOMM34-siRNAs using FuGENE 6 reagent (Roche Diagnostics), and maintained in a medium containing 10% fetal bovine serum with 800 μg/ml Geneticin for two weeks. The surviving cells were fixed with 100% methanol and stained with Giemsa solution. In another experiment, the viable cells were measured using a cell-counting kit (DOJINDO, Kumamoto, Japan). 
Results
Elevated expression of TOMM34 in CRCs.
In our earlier study, we identified a number of genes whose expression levels were frequently altered in colon tumors by the genomewide expression profile analysis of 11 CRCs and 9 adenomas of the colon using a cDNA microarray consisting of 23040 genes (10). Among the genes whose expression levels were frequently up-regulated in the 11 carcinomas, we focused in this study on a gene with in-house identification number D3124, which corresponded to TOMM34 (34-kDa translocase of the outer mitochondrial membrane). Subsequent semiquantitative RT-PCR analysis revealed its enhanced expression in 16 of 20 CRC clinical samples examined (Fig. 1a ). In addition, TOMM34 was also up-regulated in all 6 hepatocellular carcinomas, 5 of 20 lung cancers, 8 of 11 bladder cancers, 4 of 28 acute myeloid leukemias, and 10 of 51 soft tissue sarcomas in our cDNA microarray data (data not shown).
To investigate its expression in human normal tissues, we performed multiple-tissue Northern blot analysis using TOMM34 cDNA as a probe. As a result, the analysis revealed a transcript of approximately 2.0 kb by size, which was abundantly expressed in the testis and ovary, and weakly in the prostate, spleen, and colon, but no bands were detected in any of the other 11 tissues examined (Fig. 1b) . Accumulated TOMM34 protein in colorectal cancer cell lines and CRC tissues. We prepared anti-TOMM34 polyclonal antibody and examined expression of TOMM34 protein in eight CRC cell lines and 16 CRC tissues. Immunoblot analysis detected a 34-kDa band of TOMM34 that was abundantly expressed in all CRC cell lines examined. On the other hand, low levels of expression were shown in NIH3T3 and COS7, two non-cancerous cell lines (Fig. 2a) . Western blot analysis using 16 CRCs and corresponding non-cancerous mucosal tissues demonstrated its enhanced expression in 15 of the 16 tumors compared to the normal mucosa (Fig. 2b) . To examine the subcellular localization of TOMM34, we carried out immunocytochemical staining using HCT116 and RKO cells with the anti-TOMM34 antibody, which showed cytoplasmic localization of the protein (data not shown). In addition, we performed immunohistochemical staining using 12 paraffin-embedded colon cancer tissues. In 11 of the 12 tumors, TOMM34 was strongly stained in the cytoplasms of cancerous cells, but it was barely stained in non-cancerous mucosa (Fig. 3) .
Effect of TOMM34-siRNAs on growth of colon cancer cells.
To elucidate the role of TOMM34 in cancer cells, we prepared two forms of plasmids expressing siRNAs designated to suppress TOMM34 (psiU6BX-TOMM34-siD, and -siE) and a control plasmid (psiU6BX-siEGFP). We transfected HCT116 cells with psiU6BX-TOMM34-siD, psiU6BX-TOMM34-siE, or psiU6BX-siEGFP, and examined their effect on the expression of TOMM34. Western blot analysis of extracts from transfected cells revealed that psiU6BX-TOMM34-siD and psiU6BX-TOMM34-siE significantly suppressed TOMM34 expression in the transfected cells compared to psiU6BX-siEGFP ( Fig. 4a ). We additionally constructed two forms of mutant plasmids containing either a three-nucleotide substitution or a scrambled sequence of TOMM34-siD (psiU6BX-TOMM34-siDmm or psiU6BX-TOMM34-siDscr, respectively). Expectedly, both forms of mutant plasmids failed to suppress TOMM34 expression, indicating sequence specific inhibition of TOMM34 by psiU6BX-TOMM34-siD ( Fig. 4a ). We transfected plasmids co-expressing the neomycinresistance gene into HCT116 cells, and cultured them with an appropriate concentration of geneticin for 13 days. In accordance with reduced expression of TOMM34, both psiU6BX-TOMM34-siD and psiU6BX-TOMM34-siE markedly retarded the growth of transfected cells compared to psiU6BX-siEGFP. Concordant with the unchanged expression of TOMM34, psiU6BX-TOMM34-siDmm or psiU6BX-TOMM34-siDscr did not affect the number of viable cells compared with the control plasmid (Fig. 4b) . These data indicated that expression of TOMM34 is associated with growth of cancer cells.
Discussion
In this study, we focused on TOMM34, which is reported to be involved in mitochondrial import of preprotein, because it was frequently up-regulated in CRCs in our microarray data. Mitochondrial activity is enhanced in cancer cells because of augmented metabolism, which is one of the common features of highly proliferating cells. Consistent with this view, the microarray data revealed that TOMM34 expression is enhanced in a wide range of human cancers. Since energy production is essential for survival of cancer cells, suppression of mitochondrial activity should lead to their growth retardation or death. The growth suppression by siRNA to TOMM34 in cancer cells supports this notion. Human TOMM34 was identified by screening for a degenerate tetratricopeptide repeat (TPR) motif that had been found in many Tom proteins. TOMM34 contains six TPR motifs, which consist of 34 amino-acid repeat sequences, and are involved in protein-protein interaction. Proteins containing this motif play a role in diverse cellular pathways; Cdc16p, Cdc23p, and Cdc27p are components of the cyclosome/APC multicomplex, and are required for cell cycle progression through mitosis (12); FKBP4 and FKBP5, two immunophilins, are mediators of the immunoreaction (13, 14) . TOMM34 was initially predicted to play a role in mitochondrial protein translocation as a mitochondrial outer membrane protein. However, its cytoplasmic localization and its interaction with heat shock protein 90 suggested a role in maturation of newly synthesized proteins (15, 16) . The yeast two-hybrid screening system has shown that TOMM34 interacts in vitro with valosin-containing protein (VCP), an AAA (ATPases associated with a variety of cellular activities) family member, and ATPase, H + transporting, lysosomal 34 kDa, V1 subunit D (ATP6V1D or ATP6M) (16) . VCP has been shown to be essential for normal cellular function; cell cycle, homotypic membrane fusion, nuclear envelope reconstruction, postmitotic Golgi reassembly, DNA damage response, suppressor of apoptosis, and ubiquitin-dependent protein degradation (17, 18) . ATP6V1D (or ATP6M) was isolated as a gene encoding D subunit of vacuolar proton pump ATPase (19) . Notably, both VCP and ATP6V1D are essential for cell division (20) . Therefore, growth retardation of cancer cells by TOMM34 siRNAs may result from abrogated mitotic progression through inhibition of VCP and/or ATP6V1D. Since a region containing the TPR motif between codons 227 and 260 is responsible for the interaction (16) , molecules that interfere with the binding may disrupt the function of TOMM34. Additionally, TOMM34 has ATPase activity, although the activity is weaker than VCP or ATP6V1D (16) . Therefore, inhibitors of the ATPase activity may be an alternative strategy to inhibit the function of TOMM34.
It is of note that TOMM34 null mice were fertile and developed normally, suggesting that it is dispensable for development and growth under an environmentally normal condition (21) . TOMM34 is expressed abundantly in the testis and ovary, and expressed at low levels in prostate, spleen, and colon, but rarely expressed in other normal adult tissues including heart, lung, kidney and liver. Therefore, it is unlikely that the inhibition of TOMM34 will bring severe adverse effects on those vital tissues. From this point of view, inhibitors of TOMM34 should be a good anticancer drug with no or minimum adverse effects. In addition, suppression of TOMM34 resulted in the inhibition of cell growth of cancer cells, suggesting that TOMM34 plays an essential role in their growth. These findings imply that TOMM34 is a promising target for immunotherapy and/or development of anticancer drugs.
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